Cytek BioSciences, Inc. (CTKB) News
Filter CTKB News Items
CTKB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
CTKB News Highlights
- CTKB's 30 day story count now stands at 3.
- Over the past 7 days, the trend for CTKB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC are the most mentioned tickers in articles about CTKB.
Latest CTKB News From Around the Web
Below are the latest news stories about CYTEK BIOSCIENCES INC that investors may wish to consider to help them evaluate CTKB as an investment opportunity.
Cytek Biosciences to present at the 42nd Annual J.P. Morgan Healthcare ConferenceFREMONT, Calif., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. CEO Dr. Wenbin Jiang is scheduled to present and participate in a Q&A session on Thursday, January 11, at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentatio |
Insider Sell: Cytek Biosciences Inc's CTO Ming Yan Disposes of 20,000 SharesMing Yan, Chief Technology Officer of Cytek Biosciences Inc (NASDAQ:CTKB), sold 20,000 shares of the company on December 19, 2023, according to a recent SEC Filing. |
Cytek® Biosciences Introduces the Cytek Orion™ Reagent Cocktail Preparation System, the First-of-its-Kind Automated Cocktail Preparation Instrument for Flow CytometryNew System Saves Time and Resources, Improves Efficiency and Accuracy Cytek Orion The new Cytek® Orion™ reagent cocktail preparation system simplifies and accelerates laboratory workflow, assures consistent experimental results, saves time and reduces the potential for errors. FREMONT, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, announced today the introduction of the Cytek Orion™ reagent cocktail preparation system |
Insider Sell Alert: CTO Ming Yan Sells 20,000 Shares of Cytek Biosciences Inc (CTKB)In the realm of stock market movements, insider trading activity is often a significant indicator for investors. |
Cytek Biosciences to participate in the Piper Sandler 35th Annual Healthcare ConferenceFREMONT, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming Piper Sandler 35th Annual Healthcare Conference in New York, New York. Cytek management is scheduled to participate in a fireside chat on Tuesday, November 28th at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “ |
Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2023 Earnings Call TranscriptCytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2023 Earnings Call Transcript November 11, 2023 Operator: Good day and thank you for standing by. Welcome to the Cytek Biosciences Third Quarter 2023 Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker […] |
Cytek Biosciences Inc (CTKB) Q3 2023 Earnings Report SummaryOrganic Growth Amidst Macro Challenges; Full-Year Revenue Outlook Adjusted |
Cytek® Aurora™ CS System Wins BioTech Breakthrough Award for ‘Cell Sorting Product of the Year’BioTech Breakthrough Awards As the only cell sorter on the market that offers the unique ability to combine the advantages of Full Spectrum Profiling™ technology with high-performance cell sorting, the Cytek® Aurora™ CS system has been selected as the winner of the “Cell Sorting Product of the Year” award in the third annual BioTech Breakthrough Awards program. FREMONT, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, an |
Cytek Biosciences Reports Third Quarter 2023 Financial ResultsFREMONT, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights Total revenue was $48.0 million, representing 19% growth over the third quarter of 2022 Total revenue on a non-GAAP constant currency basis was $47.7 millionOrganic revenue was $41.2 million, representing an increase of 2% compared t |
Earnings Preview: Cytek Biosciences, Inc. (CTKB) Q3 Earnings Expected to DeclineCytek Biosciences, Inc. (CTKB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |